The skincare industry continues to grow at an impressive pace, and in such a situation, it may be a good move for investors to look into interesting operators in the sector. One of the companies from the sector that could be worth tracking at this point is Pacific Software Inc. (OTC:PFSF), known for the development of path-breaking products in the skincare space.
On Wednesday, the company came into focus after it announced the signing of an exclusive licensing agreement with the Regents at the University of California. By virtue of the agreement, Pacific Software would get exclusive rights to manufacture, develop, and commercialize the innovative peptide inhibitors for IDE (insulin degrading enzyme). Those enzymes have considerable importance in the fields of wound healing and cosmetics, and the inhibitors were developed at the University of California, Irvine. As per the provisions of the agreement, UC Regents would become equity partners in the company.
In the news release, it was announced that the IDE inhibitors represented a new branch of pharmacology that had been developed by Dr. Malcolm A. Leissring, who would also become the Chief Science Officer at Pacific Software owing to the agreement. The inhibitors had been developed thanks to $6 million worth of research sponsorship from the American Diabetes Association, UCI Beall Applied Innovation, and the National Institutes of Health.
The company also announced that the specific peptide IDE inhibitors that were included in the licensing agreement had been created for the purpose of dermatological applications. It was noted that these inhibitors represented a considerable leap in the field of both cosmetics and wound healing. The inhibitors help in taking collagen production to the maximum level by way of a unique new approach. It could be a good move to add Pacific Software to the watch lists at this juncture.
